Natco Pharma: Pact with Onyx bodes well

Shares of Natco Pharma may remain in focus, as it has reached a settlement with Onyx Therapeutics, Inc on patent litigation related to generic versions of 10-mg, 30-mg and 60-mg of Kyprolis. Natco Pharma has partnered with Breckenridge Pharmaceutical Inc to market the product in the United States. Kyprolis is used to treat adult patients with multiple myeloma (cancer of plasma cells) who have had at least one previous treatment for this disease.